Semax + Selank

Components

• Semax
• Selank

Community claim

Focus plus calm/anxiety relief.

Evidence of the exact combination

No controlled clinical validation of this exact marketed combination was established in this review. Ingredient evidence is not combination evidence.

Component links are not combination evidence. A commercial name’s composition may vary.

Uncertainty and risks

Separate small studies do not validate the combination; modified amidated variants remain separate.

Observed in supplier/community material; prevalence not quantified.

No dosing or mixing instructions are provided.

Source issues and references

References include queries and bibliographic handbook attributions; not all are clinical studies. Human review remains pending.

1. PMID18454096

   [Efficacy and possible mechanisms of action of a new peptide anxiolytic selank in the therapy of generalized anxiety disorders and neurasthenia].

   Zozulia AA, Neznamov GG, Siuniakov TS, Kost NV, Gabaeva MV, Sokolov OIu, Serebriakova EV, Siranchieva OA, Andriushenko AV, Telesheva ES, Siuniakov SA, Smulevich AB, Miasoedov NF, Seredenin SB.

   PMID: 18454096

   October 16, 2026

2. PMID29798983

   [The efficacy of semax in the tretament of patients at different stages of ischemic stroke].

   Gusev EI, Martynov MY, Kostenko EV, Petrova LV, Bobyreva SN.

   DOI: 10.17116/jnevro20181183261-68PMID: 29798983

   October 16, 2026

3. R06

   FDA: current bulk-substance safety-risk page
4. R19

   Semax during ischemic-stroke rehabilitation, 2018

   DOI: 10.17116/jnevro20181183261-68PMID: 29798983
5. R20

   Zozulia et al.: Selank versus medazepam, 2008

   PMID: 18454096